Battling COVID-19: using old weapons for a new enemy

Battling COVID-19: using old weapons for a new enemy

Nitin Gupta,, Rohit Kumar, Manish Soneja, Naveet Wig, Ankit Mittal, Parul Kodan

Abstract Coronavirus disease-19 (COVID-19) has reached pandemic proportions. Most of the drugs that are being tried for the treatment have not been evaluated in any randomized controlled trials. The purpose of this review was to summarize the in-vitro and in-vivo efficacy of these drugs on Severe Acute Respiratory Syndrome (SARS-CoV-2) and related viruses (SARS and Middle East Respiratory Syndrome) and evaluate their potential for re-purposing them in the management of COVID-19.

2020

Tocilizumab, hydroxychloroquine, Nitazoxanide, Lopinavir/ritonavir, SARS-CoV-2, Remdisivir

DOI: 10.1186/s40794-020-00107-1

Tropical Diseases, Travel Medicine and Vaccines

BMC

Arctic medicine. Tropical medicine